Consensus Baseline
The facts every account agrees on.
On Tuesday 27 October, a Supreme Court bench of Justices Vikram Nath and Sandeep Mehta reserved its order on petitions seeking tighter regulation of medicine prices. They include a public interest petition by advocate Kishan Chand Jain seeking mandatory generic prescriptions, controls on the launch prices of non-scheduled medicines, and limits on trade margins for medical devices. Under the Drugs (Prices Control) Order, 2013, scheduled medicines carry ceiling prices with a 16% retailer margin; non-scheduled medicines do not. The Centre has capped trade margins on anti-cancer drugs at 30% of the maximum retail price, which it says will save patients about Rs 2,500 crore a year. On 28 October, Business Standard reported the National Pharmaceutical Pricing Authority's revised prices for 543 capped cancer-drug brands and packs.
Disputed Claims
The points the accounts contradict each other on.
The numbers are the accounts this piece is built from, listed in full at the foot of the page. Tap one to jump to it.
Medicine prices in India are among the lowest in the world.
Additional Solicitor General Aishwarya Bhati said so for the Centre. The bench replied that affordability cannot be judged without India's low per capita income, and pointed to the gap between what hospitals pay for a drug and what they bill for it.
Hospital markups on medicines are justified by operating costs and quality control.
Senior advocate Mukul Rohatgi, for private hospitals, argued that hospitals must run 24 hours a day and cannot trust medicines patients bring in. The bench said hospitals could survive through other means and asked why medicine should be billed at many times its cost.
The 30% trade-margin cap delivers broad relief to cancer patients.
The Centre projected Rs 2,500 crore a year in savings, and some generic brands fell by more than 90%. But the prices of leading innovator brands are unchanged, and a patient advocacy group says excluding patient-assistance volumes diluted the cuts.
Perspectives
How each account frames the same story.
The Court's Charge
The bench treats the gap between procurement and retail prices as a regulatory failure the government has tolerated.
"Why is the entire system working to help these people," the bench asked of manufacturers, calling the National Pharmaceutical Pricing Authority a "totally defunct" body. It told the Centre: "The government is allowing this to happen. It is under the government's own eyes that it is happening." The judges dwelt on one case put to them: a distributor whose wife was being treated for cancer could buy a chemotherapy injection for Rs 11,000, while the hospital billed Rs 1.3 lakh. "Your calibration is too wayward. Rs 11,000 to Rs 1,30,000 is no calibration," the bench said. It noted that parliamentary committees had studied the problem, and questioned the timing of the cancer cap: "Why were you silent for so many years? Do not force us to ask harsh questions." Schemes like Ayushman Bharat, it added, cover only up to a limit, and families pay the rest.
The Centre's Balance
The government defends a policy that intervenes selectively rather than controlling the whole market.
Bhati told the bench that medicine prices in India are among the lowest in the world. She said the government's policy "is that the entire ecosystem is not to be controlled", and that it keeps its pricing under continuous review. The Department of Pharmaceuticals' affidavit said the 30% cancer-drug cap could cut prices by 20 to 70%, depending on the drug. The cap is meant to curb excessive markups while leaving reasonable margins for distributors and retailers. The Centre pointed to precedent: a similar cap on 42 cancer drugs in 2019 cut the prices of 526 brands and saved patients an estimated Rs 984 crore a year. Open reports that the government says pricing must balance affordability with availability and the functioning of the supply chain.
The Hospitals' Case
Private hospitals argue their pharmacy margins pay for infrastructure and protect patients from bad drugs.
Rohatgi argued that private hospitals fill gaps left by public healthcare and must keep facilities running round the clock. "Hospitals will collapse. We cannot trust patients to bring medicine from outside," he said. "If I reduce drug prices, prices across the board will increase, won't make any difference." In his account, in-house pharmacies guarantee that patients receive genuine drugs. The bench was unpersuaded: "You are a commercial hospital. You charge for everything. But why should medicine be quoted at 100, 200 times?" It added that discounts manufacturers give hospitals were "still under the cover". "You're dealing with the lives of people," it said. "Don't take it as commerce."
What the Cap Delivered
Early results of the government's main intervention show large cuts, but mostly for generics.
The day after the hearing, Business Standard reported the regulator's revised prices for 543 cancer-drug brands and packs, with cuts of up to 93%. One palbociclib brand fell from Rs 40,421.33 to Rs 2,720 a unit. But the prices of Roche's Avastin, of nivolumab and of Keytruda were unchanged, even as biosimilar versions fell by 69 to 86%. Officials said prices fell only where margins had been inflated, and an oncologist suggested the originators' margins may already have been reasonable. Aisola of the All India Drug Action Network said leaving out medicines given free under patient-assistance programmes understated margins. She called the permitted 42.86% markup "legitimising profiteering" where supply chains are short. Patient groups also say companies were asked to calculate and report their own prices, without verification.
Divergence
Where the accounts part company, and on what.
The hearing set the court's moral framing against the government's market framing, but the decisive facts arrived the next day, outside the courtroom. The cap shows that intervention works: inflated generic margins fell sharply once capped. That undercuts the Centre's defence of a light touch, and it undercuts the hospitals' claim that cutting margins changes nothing. Yet the unchanged prices of the costliest patented drugs show the limit of a tool that targets markups rather than the base price. For those drugs the margin was never the problem. Rohatgi's argument that hospitals would simply recover the money elsewhere is a prediction, not evidence, and none of these reports tests it. The shared point that survives every disagreement here is that most medicines sit outside upfront price control altogether. Still open: whether the order extends margin caps beyond cancer drugs to other medicines and consumables, whether it addresses in-house pharmacy practices, and who will verify the prices companies report.
Sources
Outlet names appear only here, never in the layers.
This article synthesises publicly available reporting for informational purposes. The perspectives summarised are paraphrased from the listed publications and reflect their respective editorial framing. Plural does not independently verify, endorse, or adopt the underlying factual claims, and provides this information on an 'as-is' basis without assuming liability for the accuracy of the original sources or the content of external links.
This summary represents an attempt at neutrality and may still contain bias; it is not presented as absolute truth.
AI is used exclusively to read and compare the independent reports behind each story, and to do nothing else. Programmatic guardrails ensure the system cannot introduce external details, infer motives, or express opinions. Automated testing immediately rejects any draft that violates these rules; failing drafts are discarded, never salvaged.
What survives this process is merely a draft, not a published piece. A human editor then scrutinises the text line by line against the original sources to minimise bias and verify accuracy. No content reaches a reader any other way.